A revenue miss and a lack of news on its depression drug candidate had shareholders down in the dumps.
News & Analysis: Sage Therapeutics
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
An important clinical trial turned in underwhelming results.
The pharma company reported positive results from an important phase 3 trial.
The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.
The biotech reported great clinical results for a late-stage drug.
The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate.
Sage's clinical pipeline continues to shine.
Investors are hoping a competitor's drug will pave the way for the company's own drug.
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.
Sage's lead drug candidate whiffs in a late-stage study.